SecBot SecBot

BEIGF

BeOne Medicines Ltd.
OTC· Pharmaceutical Preparations· CIK 0001651308 Biotech & Drug Discovery
$21.95 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $21.95
1 year
+37.6%
from $15.95 · Oct 27
30 days
0.0%
from $21.95
52-week range
$15.95–25.29
−13% from high · low Oct 27
Avg volume 20D
0
Sep 28 spike 0
Short interest
🔒 Subscribers only
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 3 reports · latest
Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BULLISH BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA global…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendRANGE

    0% above its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 8, 2026 SEC
Board member John Oyler filed a Form 144 to sell 4,940 ADSs (~$1.3M at the prevailing market price) from restricted…
144 — Impact 2/10
May 6, 2026 SEC
BeOne Medicines reported Q1 2026 total revenue of $1.51B, a 35% YoY increase, driven by BRUKINSA global sales of $1.1B…
8-K — Impact 8/10
Apr 26, 2026 Clinical trial readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advan
Apr 14, 2026 SEC
BeOne Medicines filed an 8-K to disclose additional financial information prepared under PRC GAAP in its STAR Annual…
8-K — Impact 3/10

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 26, 2026
Trial readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies Sponsor: BeOne Medicines Phase…
Apr 12, 2026
Trial readout
T-90d Trial Readout: Tislelizumab (Phase 3)
Trial: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies Sponsor: BeOne Medicines Phase…

SecBot reports

3 filings · 1 bullish · 0 bearish · 2 neutral
All BEIGF filing & press-release reports (3)